{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:17:37Z","timestamp":1776691057810,"version":"3.51.2"},"reference-count":39,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2016.01.038","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T09:47:12Z","timestamp":1454320032000},"page":"1847-1852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia"],"prefix":"10.1016","volume":"34","author":[{"given":"Francisco","family":"Sanz-Herrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concepci\u00f3n","family":"Gimeno-Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Tormo-Palop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrella","family":"Fern\u00e1ndez-Fabrellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Briones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"Cervera-Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Blanquer-Olivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.01.038_bib0200","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0205","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/315760","article-title":"Prospective study of prognostic factors in community-acquired bacteraemic pneumococcal disease in 5 countries","volume":"182","author":"Kalin","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0029-1202938","article-title":"Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention","volume":"30","author":"Lynch","year":"2009","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thorax.56.4.296","article-title":"Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.038_bib0220","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/321808","article-title":"Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria","volume":"33","author":"Ros\u00f3n","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.038_bib0225","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/cid\/ciq076","article-title":"Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study","volume":"52","author":"Majumdar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0230","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.rmed.2009.06.013","article-title":"Is it possible to predict which patients with mild pneumonias will develop hypoxemia?","volume":"103","author":"Sanz","year":"2009","journal-title":"Respir Med"},{"issue":"June","key":"10.1016\/j.vaccine.2016.01.038_bib0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2334-4-21","article-title":"Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited","volume":"4","author":"Martens","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.038_bib0240","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2016.01.038_bib0245","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","article-title":"Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults","volume":"32","author":"Grabenstein","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.038_bib0250","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1183\/09031936.00176309","article-title":"Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia","volume":"36","author":"Luj\u00e1n","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.038_bib0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/thx.2009.123612","article-title":"Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes","volume":"65","author":"Garcia-Vidal","year":"2010","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.038_bib0260","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1183\/09031936.00050413","article-title":"Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes","volume":"43","author":"Burgos","year":"2014","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.vaccine.2016.01.038_bib0265","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0270","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0275","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa","volume":"371","author":"von Gottberg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0280","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jinf.2011.10.015","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands","volume":"64","author":"Strutton","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0285","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2014.04.066","article-title":"European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era","volume":"32","author":"Navarro Torn\u00e9","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jinf.2011.06.002","article-title":"Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain","volume":"63","author":"Mu\u00f1oz-Almagro","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0295","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","article-title":"Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines","volume":"14","author":"Isaacman","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0300","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0305","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJM199111213252101","article-title":"The protective efficacy of polyvalent pneumococcal polysaccharide vaccine","volume":"325","author":"Shapiro","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0310","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0315","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.02.087","article-title":"Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial","volume":"28","author":"Russell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0320","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"3364","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0325","series-title":"Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-S18","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"issue":"9","key":"10.1016\/j.vaccine.2016.01.038_bib0330","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1086\/374624","article-title":"Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential","volume":"187","author":"Brueggemann","year":"2003","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.038_bib0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1469-0691.2012.03895.x","article-title":"Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia","volume":"19","author":"Burgos","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0340","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/1471-2334-13-492","article-title":"High incidence of septic shock caused by Streptococcus pneumoniae serotype 3-a retrospective epidemiological study","volume":"13","author":"Ahl","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.038_bib0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3346\/jkms.2013.28.1.4","article-title":"Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance","volume":"28","author":"Song","year":"2013","journal-title":"Korean Med Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.038_bib0350","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/cir354","article-title":"The spectrum of pneumococcal empyema in adults in the early 21st century","volume":"53","author":"Burgos","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.038_bib0355","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1469-0691.2011.03692.x","article-title":"Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes","volume":"18","author":"Cill\u00f3niz","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2016.01.038_bib0360","doi-asserted-by":"crossref","first-page":"e26587","DOI":"10.1371\/journal.pone.0026587","article-title":"Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence","volume":"6","author":"Sanchez","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.038_bib0365","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4104\/pcrj.2010.00049","article-title":"What is the role of pulse oximetry in the assessment of patients with community-acquired pneumonia in primary care?","volume":"19","author":"Bewick","year":"2010","journal-title":"Prim Care Respir J"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.038_bib0370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1742-6723.2007.01003.x","article-title":"Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool","volume":"19","author":"Buising","year":"2007","journal-title":"Emerg Med Australas"},{"key":"10.1016\/j.vaccine.2016.01.038_bib0375","first-page":"232","article-title":"Consenso sobre la vacunaci\u00f3n anti-neumoc\u00f3cica en el adulto con patolog\u00eda de base","volume":"26","author":"Picazo","year":"2013","journal-title":"Rev Esp Quimioter"},{"issue":"40","key":"10.1016\/j.vaccine.2016.01.038_bib0380","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.40.20922","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008\u20132011","volume":"19","author":"Gutierrez Rodriguez","year":"2014","journal-title":"Euro Surveill"},{"issue":"April","key":"10.1016\/j.vaccine.2016.01.038_bib0385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-13-175","article-title":"Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model","volume":"13","author":"Pradas","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2016.01.038_bib0390","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.vaccine.2014.03.054","article-title":"Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001\u20132013","volume":"32","author":"Guevara","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T16:57:52Z","timestamp":1537030672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X16000827"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}